Get started
Author

Salvador Blanch

Observed names: Blanch, Salvador, Blanch-Tormo, Salvador, Salvador Blanch-Tormo, salvador blanch
ORCID: 0009-0008-9553-2179
Observed ORCID: 0009-0008-9553-2179
OpenAlex ID: A5112899140
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
2022 · José Manuel Pérez-García, Marta Vaz Batista, et al. · Neuro-Oncology · 261
PDF
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
2024 · Marta Vaz Batista, José Manuel Pérez-García, et al. · Med · 58
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2025 · María Gion, Isabel Blancas, et al. · Nature Medicine · 42
PDF
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
2019 · Barbara Adamo, Meritxell Bellet, et al. · Breast Cancer Research · 38
PDF
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
2024 · Antonio Llombart-Cussac, José Manuel Pérez-Garcia, et al. · EClinicalMedicine · 29
PDF
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial
2025 · José Manuel Pérez-García, María Gion, et al. · EClinicalMedicine · 26
PDF
A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types
2020 · Belén Pastor-Navarro, María García-Flores, et al. · International Journal of Molecular Sciences · 21
PDF
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.
2024 · José Manuel Pérez García, María Gión, et al. · Journal of Clinical Oncology · 20
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
2020 · Luis Manso, Cristina Hernando, et al. · The Breast · 14
Abstract PD8-02: Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
2023 · Manuel Ruiz Borrego, Pablo Tolosa, et al. · Cancer Research · 11
Abstract PS16-02: Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2024 · Maria Gion, Patricia Cortez-Castedo, et al. · Cancer Research · 9
Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study
2024 · Marta Vaz Batista, José Manuel Pérez-García, et al. · Cancer Research · 7
Abstract PD7-02: Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial
2023 · José Manuel Pérez-García, Marta Vaz Batista, et al. · Cancer Research · 7
Abstract CT191: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
2021 · Luis Manso, Fernando Salvador, et al. · Cancer Research · 7
Abstract P3-06-02: TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis
2023 · Aleix Prat, Tomás Pascual, et al. · Cancer Research · 6
Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study
2022 · Marta Vaz Batista, Patricia Cortez, et al. · Cancer Research · 5
Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
2023 · Salvador Blanch, Juan Miguel Gil-Gil, et al. · Clinical & Translational Oncology · 4
PDF
Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
2026 · Benedetta Conte, Fara Brasó-Maristany, et al. · Clinical Cancer Research · 3
Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
2022 · Maria Cortes, Alfonso Cortés Salgado, et al. · Journal of Clinical Oncology · 3
Abstract PS12-08: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)
2021 · Luis Manso, Patricia Villagrasa, et al. · Cancer Research · 3
Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)
2021 · Eva Ciruelos, Tomás Pascual, et al. · Cancer Research · 3
806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer
2020 · Luis Manso, Patricia Villagrasa, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Data from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
2026 · Benedetta Conte, Fara Brasó-Maristany, et al. · 1
Abstract P1-02-06: Efficacy analysis & updated safety from the phase 2 PRIMED study of prophylactic granulocyte-colony stimulating factor (G-CSF) & loperamide for patients (pts) with HER2-negative advanced breast cancer (ABC) treated w/ sacituzumab govitecan (SG)
2025 · María Gion, Manuel Ruiz-Borrego, et al. · Clinical Cancer Research · 1
Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation
2025 · Laura Lema, José Manuel Pérez-García, et al. · Cancers · 1
PDF
Works count: 50
Citation count: 589
H-index: 10
I10-index: 10
Year
Topic
Type